A point that merits consideration is that the current in vitro metabolic fuel deficiency paradigm is not an exact replication of pathophysiological exogenous insulin-induced reductions in brain tissue glucose levels in vivo that may result from iatrogenic hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.